Abstract
The FDA has approved a fixed-dose dual bronchodilator that combines glycopyrrolate and formoterol fumarate in a pressurized, metered-dose inhaler. The drug, marketed as Bevespi Aerosphere, is indicated for long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) (http://1.usa.gov/1qVyi94). Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) while formoterol fumarate is a long-acting β2-agonist (LABA). Manufacturer AstraZeneca said in a statement that the combination medication is the first FDA-approved product using its unique technology that distributes drug crystals in a uniform suspension formed with porous, low-density phospholipid particles. The technology prevents the drug crystals from settling or intermingling, allowing consistent doses of different drugs to be dispensed from a single pressurized metered-dose inhaler (http://bit.ly/1VBpmTq).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
